Iovance Biotherapeutics, Inc. (IOVA)

NASDAQ: IOVA · Real-Time Price · USD

5.41

+0.28 (5.46%)

At close: Mar 9, 2026, 4:00 PM EDT

5.39

-0.02 (-0.37%)

After-hours: Mar 9, 2026, 6:43 PM EDT

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Innovating, Developing & Commercializing Therapies Using Autologous TIL	263.50M	164.07M	1.19M	-	-
Innovating, Developing & Commercializing Therapies Using Autologous TIL Growth	60.60%	13698.99%	-	-	-
Total	263.50M	164.07M	1.19M	-	-
Total Growth	60.60%	13698.99%	-	-	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
United States	259.01M	161.04M	-	-	-
United States Growth	60.83%	-	-	-	-
Rest of World	4.49M	3.03M	1.19M	-	-
Rest of World Growth	48.30%	154.58%	-	-	-
Total	263.50M	164.07M	1.19M	-	-
Total Growth	60.60%	13698.99%	-	-	-

Source: S&P Global Market Intelligence.